Syntax Bio
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
$14.4MSeries A+
Role not disclosedDB
DCVC Bio
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $248.4M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionLatus Bio, Inc.
Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2
$97MSeries A
Role not disclosedSidewinder Therapeutics
Develops next-generation bispecific ADCs for cancer treatment
$137MSeries B
Role not disclosed